← Back to all news
OpenAI Blog

OpenAI acquires Orchestra Bio

Read the original on OpenAI Blog →

OpenAI has announced its acquisition of Orchestra Bio, a company that specializes in AI‑powered operations for life sciences research and development. The move aims to help biopharma teams accelerate drug development and advance new treatments by integrating advanced AI tools into their R&D workflows.

Machine-generated by The Flow from the publisher's headline and feed description — not written or checked by a human. The full article lives at OpenAI Blog.

Related stories

OpenAI Blog
Jan 15

Investing in Merge Labs

OpenAI is investing in Merge Labs to support new brain computer interfaces that bridge biological and artificial intelligence to maximize human ability, agency, and experience.

More like this →
OpenAI Blog
Dec 11, 2015

Introducing OpenAI

OpenAI is a non-profit artificial intelligence research company. Our goal is to advance digital intelligence in the way that is most likely to benefit humanity as a whole, unconstrained by a need to generate financial return.

More like this →
OpenAI Blog
Jan 8

OpenAI for Healthcare

OpenAI for Healthcare enables secure, enterprise-grade AI that supports HIPAA compliance—reducing administrative burden and supporting clinical workflows.

More like this →